Global Triage B-Type Natriuretic Peptide (BNP) Testing Market, By Application (Acute Myocardial Infarction (AMI), Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF), Others), End-Use (Laboratory Testing, Point of Care Testing) – Industry Trends and Forecast to 2030.
Triage B-Type Natriuretic Peptide (BNP) Testing Market Analysis and Size
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, claiming the lives of an estimated 17.9 million people each year. CVDs are a group of heart and blood vessel disorders that include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and others. Heart attacks and strokes account for more than four out of every five CVD deaths, and one-third of these deaths occur in people under the age of 70. Growing cardiac disease incidence, rising diagnostic awareness, and increasing demand for effective cardiac disease diagnostic tests are some of the major factors expected to drive the growth of the triage B-type natriuretic peptide (BNP) testing market from 2023 to 2030.
Data Bridge Market Research analyses that the triage b-type natriuretic peptide (BNP) testing market which was USD 5 billion in 2022, is expected to reach USD 9.60 billion by 2030, at a CAGR of 8.50% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Triage B-Type Natriuretic Peptide (BNP) Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Application (Acute Myocardial Infarction (AMI), Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF), Others), End-Use (Laboratory Testing, Point of Care Testing)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Ortho-Clinical Diagnostics (U.S.), Singulex, Inc. (U.S.), Alere, Inc. (U.S.), Siemens Healthcare Diagnostics, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Randox Laboratories Ltd. (U.K.), Biomerieux (France), Bio-Rad Laboratories Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
B-type natriuretic peptide, also known as brain natriuretic peptide, is a 32-amino acid (AA) polypeptide produced by cardiac ventricles in response to cardiac muscle cell overstretching. Calcium ions control BNP production. BNP and ANP (atrial natriuretic peptide) function similarly and have the same biochemical activity. ANP and BNP play an important role in reducing systemic vascular resistance, which leads to a decrease in blood volume, a decrease in blood pressure, and an increase in cardiac output.
Triage B-Type Natriuretic Peptide (BNP) Testing Market Dynamics
Drivers
- Rise in awareness about diagnostics
BNP testing is one of the most important diagnostic tests used to treat cardiovascular disease. The primary purpose of BNP screening is to prevent cardiovascular diseases such as cardiac arrest and heart failure. Furthermore, a BNP spike (greater than 100 pg/ml) indicates recurrent heart disease, such as cardiac failure. This elevated value indicates a chronic medical condition known as left ventricular dysfunction. Immunoassay techniques were used to collect data. In contrast, BNP levels rise during renal failure, but testing for renal failure is not recommended due to large variations in performance. These are the certain factors that boost the growth of the market.
- Growing occurrence of cardiac diseases
The primary function of b-type natriuretic peptides is to reduce vascular system resistance in the body. This reduces the volume of blood that rushes to the heart and, as a result, lowers blood pressure. The rising prevalence of cardiac disorders is a major factor driving the B-type natriuretic peptide test market growth. This is likely to continue throughout the forecast period.
Opportunities
- Increasing demand for effectual cardiac disease diagnostic test
Growing incidence of cardiac diseases, rising awareness about diagnostics and increasing demand for effectual cardiac disease diagnostic test are some of the major factors expected to drive the growth of triage B-type natriuretic peptide (BNP) testing market in the forecast period of 2022 to 2030. Natriuretic peptides promote urine excretion, relax blood vessels, lower blood pressure, and reduce the workload on the heart. They are natural defence mechanisms designed to protect the heart from stress.
Restraints/Challenges
- Lack of awareness about health
Lack of awareness about health and welfare, as well as a lack of proper medical facilities, may pose a significant impediment to the overall growth of this market in the coming years, particularly in underdeveloped and emerging nations.
This triage b-type natriuretic peptide (BNP) testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the triage b-type natriuretic peptide (BNP) testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Triage B-Type Natriuretic Peptide (BNP) Testing Market Scope
The triage b-type natriuretic peptide (BNP) testing market is segmented on the basis of application and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Acute Myocardial Infarction (AMI)
- Acute Coronary Syndrome (ACS)
- Congestive Heart Failure (CHF)
- Others
End-Use
- Laboratory Testing
- Point of Care Testing
Triage B-Type Natriuretic Peptide (BNP) Testing Market Regional Analysis/Insights
The triage b-type natriuretic peptide (BNP) testing market is analyzed and market size insights and trends are provided by country, application and end use as referenced above.
The countries covered in the triage b-type natriuretic peptide (BNP) testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the triage b-type natriuretic peptide (BNP) testing market because of the region's well-developed healthcare infrastructure and favourable reimbursement policies.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The triage b-type natriuretic peptide (BNP) testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for triage b-type natriuretic peptide (BNP) testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the triage b-type natriuretic peptide (BNP) testing market. The data is available for historic period 2011-2021.
Competitive Landscape and Triage B-Type Natriuretic Peptide (BNP) Testing Market Share Analysis
The triage b-type natriuretic peptide (BNP) testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to triage b-type natriuretic peptide (BNP) testing market.
Some of the major players operating in the triage b-type natriuretic peptide (BNP) testing market are:
- Abbott (U.S.)
- Ortho-Clinical Diagnostics (U.S.)
- Singulex, Inc. (U.S.)
- Alere, Inc. (U.S.)
- Siemens Healthcare Diagnostics, Inc. (U.S.)
- Beckman Coulter, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Randox Laboratories Ltd. (U.K.)
- Biomerieux (France)
- Bio-Rad Laboratories Inc. (U.S.)
SKU-